|
covid-19 |
146 |
|
sars-cov-2 |
93 |
|
humans |
54 |
|
adult |
52 |
|
middle aged |
45 |
|
female |
39 |
|
male |
39 |
|
aged |
34 |
|
adolescent |
31 |
|
medical sciences |
29 |
|
hong kong - epidemiology |
26 |
|
vaccine |
26 |
|
seroepidemiologic studies |
23 |
|
atrial fibrillation |
22 |
|
child |
22 |
|
child, preschool |
22 |
|
viral load |
20 |
|
antibodies, viral - blood |
19 |
|
china - epidemiology |
19 |
|
risk factors |
19 |
|
diagnosis |
18 |
|
gastroenterology |
18 |
|
influenza |
18 |
|
influenza a virus, h1n1 subtype - immunology |
18 |
|
age factors |
17 |
|
aged, 80 and over |
17 |
|
cross-sectional studies |
17 |
|
disease outbreaks - statistics & numerical data |
17 |
|
hong kong |
17 |
|
antibody |
16 |
|
coronavirus |
16 |
|
covid-19 vaccine |
16 |
|
healthcare workers |
16 |
|
hepatitis b |
16 |
|
hospital policies |
16 |
|
infant |
16 |
|
interferon beta-1b |
16 |
|
perceived stress |
16 |
|
psychological wellbeing |
16 |
|
severe acute respiratory syndrome |
16 |
|
anosmia |
15 |
|
immunoglobulin g - blood |
15 |
|
influenza a virus, h1n1 subtype - immunology - isolation and purification - pathogenicity |
15 |
|
molnupiravir |
15 |
|
olfactory dysfunction |
15 |
|
pandemics |
15 |
|
saliva |
15 |
|
biomarkers |
14 |
|
blotting, western |
14 |
|
cohort studies |
14 |
|
complications |
14 |
|
coronavac |
14 |
|
coronavirus infection |
14 |
|
health outcomes |
14 |
|
immune activation |
14 |
|
intestine |
14 |
|
mortality |
14 |
|
replication |
14 |
|
sars-cov |
14 |
|
severity of illness index |
14 |
|
thyroid function tests |
14 |
|
alanine transaminase - blood |
13 |
|
disease severity |
13 |
|
epidemiology |
13 |
|
nirmatrelvir-ritonavir |
13 |
|
pneumonia |
13 |
|
thyroid gland |
13 |
|
treatment outcome |
13 |
|
clarithromycin |
12 |
|
follow-up studies |
12 |
|
incidence |
12 |
|
metabolomics |
12 |
|
prognosis |
12 |
|
retrospective studies |
12 |
|
young adult |
12 |
|
antiviral agents - therapeutic use |
11 |
|
bnt162b2 |
11 |
|
chronic hepatitis b |
11 |
|
genotype |
11 |
|
immunogenicity |
11 |
|
intradermal |
11 |
|
lung - radiography |
11 |
|
pandemic |
11 |
|
serology |
11 |
|
thyroiditis |
11 |
|
virus replication |
11 |
|
age |
10 |
|
all-cause pneumonia |
10 |
|
antiviral therapy |
10 |
|
burkholderia pseudomallei |
10 |
|
carcinoma |
10 |
|
covid19 |
10 |
|
cytokines - blood |
10 |
|
diagnostics |
10 |
|
disease outbreaks |
10 |
|
feces - virology |
10 |
|
gastrointestinal haemorrhage |
10 |
|
hamster |
10 |
|
herd immunity |
10 |
|
influenza a virus, h1n1 subtype - isolation and purification |
10 |
|
influenza vaccine |
10 |
|
influenza vaccines - administration and dosage |
10 |
|
influenza, human - immunology - pathology - virology |
10 |
|
influenza, human - mortality |
10 |
|
interferon |
10 |
|
interrupted time series analysis |
10 |
|
ischemic stroke |
10 |
|
linker-immunodominant site |
10 |
|
melioidosis |
10 |
|
mycobacterium tuberculosis |
10 |
|
patient admission - statistics and numerical data |
10 |
|
plasma |
10 |
|
pneumococcal conjugate vaccines |
10 |
|
population surveillance |
10 |
|
population-based electronic health records |
10 |
|
reverse transcriptase polymerase chain reaction |
10 |
|
sars virus - isolation and purification |
10 |
|
sex difference |
10 |
|
smell impairment |
10 |
|
spike protein |
10 |
|
time factors |
10 |
|
time in therapeutic range |
10 |
|
vaccination - methods |
10 |
|
airborne infection |
9 |
|
antibodies, neutralizing - blood |
9 |
|
antibody titer |
9 |
|
antiviral agents - administration and dosage - therapeutic use |
9 |
|
bioaerosols |
9 |
|
blood donors |
9 |
|
chest x-ray |
9 |
|
chronic kidney disease |
9 |
|
coronavirus - genetics - isolation & purification |
9 |
|
covid‐19 |
9 |
|
cross infection - epidemiology - immunology |
9 |
|
elderly |
9 |
|
enzyme-linked immunosorbent assay |
9 |
|
euthyroid sick syndromes |
9 |
|
immunoglobulin g - analysis - immunology |
9 |
|
influenza, human - epidemiology - immunology - virology |
9 |
|
lipidomics |
9 |
|
markov chains |
9 |
|
membrane glycoproteins - analysis |
9 |
|
monte carlo method |
9 |
|
myocardial infarction - mortality - prevention and control |
9 |
|
myocarditis |
9 |
|
neutralization tests |
9 |
|
neutralizing antibody |
9 |
|
nomogram |
9 |
|
nucleocapsid proteins - genetics - immunology |
9 |
|
operating rooms |
9 |
|
outbreak |
9 |
|
phosphatidic acid phosphatases |
9 |
|
pneumococcal vaccines - administration and dosage |
9 |
|
pneumonia, viral - epidemiology - immunology - virology |
9 |
|
point-of-care testing |
9 |
|
prediction model |
9 |
|
recombinant proteins - analysis - immunology |
9 |
|
reproducibility of results |
9 |
|
resting-state fmri |
9 |
|
rhinovirus |
9 |
|
ribavirin - therapeutic use |
9 |
|
sars virus - isolation & purification |
9 |
|
sars‐cov‐2 |
9 |
|
severe acute respiratory syndrome - epidemiology - immunology - virology |
9 |
|
specific |
9 |
|
stroke - mortality - prevention and control |
9 |
|
viral disease |
9 |
|
viral envelope proteins - analysis |
9 |
|
vitamin a |
9 |
|
white cell count |
9 |
|
2009 h1n1 influenza |
8 |
|
25-hydroxycholesterol |
8 |
|
a(h1n1)pdm09 |
8 |
|
a(h3n2) |
8 |
|
acute infection |
8 |
|
adjuvant |
8 |
|
aerosolised |
8 |
|
am580 |
8 |
|
animal experiment |
8 |
|
anti-bacterial agents - therapeutic use |
8 |
|
antibody blood level |
8 |
|
antibody detection |
8 |
|
antibody formation |
8 |
|
antibody response |
8 |
|
asymptomatic |
8 |
|
asymptomatic infection |
8 |
|
autoimmunity |
8 |
|
b-cell suppression |
8 |
|
case study |
8 |
|
conjunctiva |
8 |
|
convalescent |
8 |
|
delns1-ncov-rbd laiv |
8 |
|
dendritic cell |
8 |
|
dialysis |
8 |
|
disease progression |
8 |
|
early |
8 |
|
functional brain network |
8 |
|
ganglioside gm1 antibody |
8 |
|
gastric cancer |
8 |
|
glycolipids |
8 |
|
hemagglutination inhibition tests |
8 |
|
hepatitis b vaccination |
8 |
|
hepatitis c |
8 |
|
high-risk |
8 |
|
hla‐dp |
8 |
|
hospitalized |
8 |
|
ifn‐γ pathway |
8 |
|
imiquimod |
8 |
|
influenza a virus, h1n1 subtype - genetics - immunology - isolation and purification |
8 |
|
influenza a virus, h1n1 subtype - genetics - isolation & purification - physiology |
8 |
|
influenza a virus, h1n1 subtype - isolation & purification - pathogenicity |
8 |
|
influenza vaccines - immunology |
8 |
|
influenza virus |
8 |
|
influenza, human - epidemiology - pathology - virology |
8 |
|
influenza, human - epidemiology - virology |
8 |
|
influenza, human - immunology |
8 |
|
integrative-omics |
8 |
|
interventions |
8 |
|
intranasal |
8 |
|
long covid |
8 |
|
metalloimmunity |
8 |
|
metalloproteomics |
8 |
|
mitochondrial dysfunction |
8 |
|
nanopore sequencing |
8 |
|
naproxen |
8 |
|
natural history |
8 |
|
nsp1 |
8 |
|
obesity |
8 |
|
older patients |
8 |
|
olfactory training |
8 |
|
oseltamivir |
8 |
|
phase-1 |
8 |
|
phospholipids |
8 |
|
pneumococcal vaccination |
8 |
|
promoter regions, genetic |
8 |
|
randomized controlled trial |
8 |
|
remdesivir |
8 |
|
renal failure |
8 |
|
respiratory system - virology |
8 |
|
respiratory tract infection |
8 |
|
rna, viral - genetics |
8 |
|
rt-pcr |
8 |
|
rt‐pcr |
8 |
|
sars virus |
8 |
|
screening |
8 |
|
seasons |
8 |
|
serial |
8 |
|
shedding |
8 |
|
smell loss |
8 |
|
sphingolipids |
8 |
|
stem cells |
8 |
|
stool |
8 |
|
t cell |
8 |
|
tlr7 agonist |
8 |
|
urine |
8 |
|
urine - virology |
8 |
|
vaccination |
8 |
|
viral load - physiology |
8 |
|
virus cultivation |
8 |
|
virus shedding |
8 |
|
xaf1 |
8 |
|
accuracy |
7 |
|
adiponectin |
7 |
|
alanine aminotransferase blood level |
7 |
|
alanine transaminase - metabolism |
7 |
|
antiviral agents - pharmacology |
7 |
|
antiviral compounds |
7 |
|
anxiety |
7 |
|
autoantibodies |
7 |
|
avian influenza |
7 |
|
bacteriological techniques - methods |
7 |
|
carcinoma, hepatocellular - virology |
7 |
|
cell line |
7 |
|
chlorogenic acid - chemistry - pharmacology |
7 |
|
chronic viral hepatitis |
7 |
|
common cold - genetics |
7 |
|
coronavirus 229e, human - genetics - physiology |
7 |
|
coronavirus infections - genetics |
7 |
|
culture media - chemistry |
7 |
|
diagnostic |
7 |
|
diagnostic test accuracy study |
7 |
|
diarrhea - epidemiology - microbiology |
7 |
|
drug response |
7 |
|
drug synergism |
7 |
|
drug therapy, combination |
7 |
|
entecavir |
7 |
|
epidemics |
7 |
|
etv |
7 |
|
evaluation |
7 |
|
fhl2 |
7 |
|
flavivirus |
7 |
|
flavonoids - chemistry - pharmacology |
7 |
|
glycyrrhizic acid - chemistry - pharmacology |
7 |
|
h7n9 |
7 |
|
hbsag |
7 |
|
helicobacter pylori |
7 |
|
hepatitis b e antigens - metabolism |
7 |
|
hepatitis b virus |
7 |
|
hepatitis b virus - physiology |
7 |
|
hepatitis b, chronic - blood - drug therapy - virology |
7 |
|
hepatitis b, chronic - complications |
7 |
|
hepatitis b, chronic - enzymology - pathology |
7 |
|
high infection rate |
7 |
|
homeodomain proteins - genetics - metabolism |
7 |
|
human herpesvirus 6b |
7 |
|
hyperglycemia |
7 |
|
icu patient |
7 |
|
immunity |
7 |
|
infectivity |
7 |
|
influenza a virus, h1n1 subtype - genetics |
7 |
|
influenza a virus, h1n1 subtype - immunology - pathogenicity |
7 |
|
influenza, human - drug therapy - epidemiology - virology |
7 |
|
interferon-alpha - pharmacology |
7 |
|
interferon-beta - pharmacology |
7 |
|
klebsiella infections - epidemiology - microbiology |
7 |
|
klebsiella oxytoca - classification - genetics - isolation and purification - pathogenicity |
7 |
|
leptin |
7 |
|
lightmix e-gene |
7 |
|
lipid peroxidation |
7 |
|
liver cirrhosis - enzymology - pathology |
7 |
|
liver neoplasms - virology |
7 |
|
lopinavir |
7 |
|
mice |
7 |
|
microbial sensitivity tests |
7 |
|
middle east respiratory syndrome |
7 |
|
miltefosine |
7 |
|
nasopharynx/virology |
7 |
|
nucleos(t)ide analogue |
7 |
|
nucleoside analogue |
7 |
|
oseltamivir - administration and dosage - therapeutic use |
7 |
|
pathogenesis |
7 |
|
phylodynamic |
7 |
|
phylogenetic |
7 |
|
polymerase chain reaction |
7 |
|
post–acute covid-19 syndrome |
7 |
|
pregnancy |
7 |
|
prevalence |
7 |
|
protein carbonylation |
7 |
|
pyrimidinones - pharmacology |
7 |
|
real-time rt-pcr |
7 |
|
reinfection |
7 |
|
ribavirin - pharmacology |
7 |
|
rimantadine - pharmacology |
7 |
|
route of transmission |
7 |
|
sars virus - drug effects |
7 |
|
sars virus - genetics - physiology |
7 |
|
sensitivity and specificity |
7 |
|
severe |
7 |
|
severe acute respiratory syndrome - blood - physiopathology - urine - virology |
7 |
|
severe acute respiratory syndrome - genetics |
7 |
|
severe acute respiratory syndrome - virology |
7 |
|
single-tube nested |
7 |
|
stability |
7 |
|
surface antigen |
7 |
|
t helper 1 responses |
7 |
|
tfh |
7 |
|
type 2 diabetes |
7 |
|
untranslated |
7 |
|
viral genome |
7 |
|
viral plaque assay |
7 |
|
virus |
7 |
|
zika |
7 |
|
2019 novel coronavirus |
6 |
|
adefovir |
6 |
|
administration, oral |
6 |
|
alanine aminotransferase |
6 |
|
amoxicillin-potassium clavulanate combination - administration & dosage |
6 |
|
antibody assay |
6 |
|
antigenic cartography |
6 |
|
antigenic distance |
6 |
|
antigenic field |
6 |
|
asian continental ancestry group - statistics & numerical data |
6 |
|
automated |
6 |
|
bile |
6 |
|
biliary |
6 |
|
blood donors - statistics and numerical data |
6 |
|
blood pressure monitoring, ambulatory |
6 |
|
booster vaccine |
6 |
|
bowel preparation |
6 |
|
burden of disease |
6 |
|
cancer |
6 |
|
carcinoma, hepatocellular - ethnology - pathology - virology |
6 |
|
carcinoma, hepatocellular - etiology |
6 |
|
carcinoma, hepatocellular - etiology - pathology - surgery - virology |
6 |
|
carrier state - epidemiology - pathology |
6 |
|
chemokine |
6 |
|
cholangiocarcinoma |
6 |
|
cholangitis |
6 |
|
cirrhosis |
6 |
|
clarithromycin - adverse effects - contraindications |
6 |
|
coinfection |
6 |
|
colchicine - adverse effects - contraindications |
6 |
|
colon cancer |
6 |
|
colon neoplasms |
6 |
|
colonoscopy |
6 |
|
community |
6 |
|
competitive elisa |
6 |
|
cost |
6 |
|
cross infection - complications |
6 |
|
curative colectomy |
6 |
|
cytokine |
6 |
|
daptomycin |
6 |
|
decolonization |
6 |
|
diagnostic test evaluation |
6 |
|
dna, viral - analysis |
6 |
|
dna, viral - blood |
6 |
|
drug interactions |
6 |
|
elasticity imaging techniques |
6 |
|
elderly care |
6 |
|
endocrinology |
6 |
|
enzyme-linked immunosorbent assay - methods |
6 |
|
eosinophil |
6 |
|
face mask |
6 |
|
fatty acids |
6 |
|
fibroscan |
6 |
|
flow cytometry |
6 |
|
follow up |
6 |
|
genome subtraction |
6 |
|
genotype 1 |
6 |
|
genotype 6 |
6 |
|
guanine - analogs and derivatives - therapeutic use |
6 |
|
hbeag |
6 |
|
hbv dna |
6 |
|
health care workers |
6 |
|
healthcare resource |
6 |
|
hepacivirus - classification - genetics - pathogenicity |
6 |
|
hepatitis b - complications |
6 |
|
hepatitis b antibodies - blood |
6 |
|
hepatitis b e antigens - blood |
6 |
|
hepatitis b surface antigen |
6 |
|
hepatitis b surface antigens - immunology |
6 |
|
hepatitis b virus - genetics - immunology - isolation & purification |
6 |
|
hepatitis b virus - isolation and purification |
6 |
|
hepatitis b(e) antigen |
6 |
|
hepatitis b, chronic - drug therapy - virology |
6 |
|
hepatitis b, chronic - epidemiology - pathology |
6 |
|
hepatitis b, chronic - ethnology - immunology - pathology |
6 |
|
hepatitis c, chronic - complications - metabolism - virology |
6 |
|
hiv protease inhibitors - therapeutic use |
6 |
|
host-pathogen interactions |
6 |
|
hpyv6 |
6 |
|
human rhinovirus |
6 |
|
hypertension |
6 |
|
illumina sequencing |
6 |
|
immune imprinting |
6 |
|
immune response |
6 |
|
immunosuppression - adverse effects |
6 |
|
infusions, intravenous |
6 |
|
intensive care unit |
6 |
|
intra-host diversity |
6 |
|
kidney failure - complications |
6 |
|
kinetics |
6 |
|
lactobacillus rhamnosus gg |
6 |
|
lamivudine |
6 |
|
lamivudine - adverse effects - therapeutic use |
6 |
|
length of stay |
6 |
|
linezolid |
6 |
|
liver - pathology |
6 |
|
liver - pathology - virology |
6 |
|
liver cirrhosis - ethnology - pathology - virology |
6 |
|
liver cirrhosis - etiology |
6 |
|
liver neoplasms - ethnology - pathology - virology |
6 |
|
liver neoplasms - etiology - pathology - surgery - virology |
6 |
|
liver stiffness |
6 |
|
longitudinal |
6 |
|
longitudinal studies |
6 |
|
malignancy |
6 |
|
mass screening |
6 |
|
memory t cell |
6 |
|
microbiota |
6 |
|
mitochondrial dysfunction (md) |
6 |
|
mobile diagnostic |
6 |
|
multivariate analysis |
6 |
|
nasopharyngeal |
6 |
|
nasopharyngeal swab |
6 |
|
nsp2 |
6 |
|
nucleocapsid protein |
6 |
|
nucleocapsid proteins - isolation & purification |
6 |
|
ofloxacin |
6 |
|
omeprazole - therapeutic use |
6 |
|
omicron |
6 |
|
on-site screening |
6 |
|
pneumocytis |
6 |
|
pneumonia admission |
6 |
|
polyethylene glycol |
6 |
|
polyomavirus |
6 |
|
pooling |
6 |
|
population aging |
6 |
|
pregnancy complications, infectious - diagnosis - therapy |
6 |
|
pulse therapy, drug |
6 |
|
pyrimidinones - therapeutic use |
6 |
|
questionnaires |
6 |
|
recurrence |
6 |
|
respiratory |
6 |
|
respiratory syncytial virus |
6 |
|
reverse transcriptase polymerase chain reaction - methods |
6 |
|
risk assessment |
6 |
|
ritonavir - therapeutic use |
6 |
|
rna, viral - genetics - isolation & purification |
6 |
|
rt-lamp |
6 |
|
sars virus - genetics - isolation & purification |
6 |
|
sars-cov-1 |
6 |
|
sars-cov-2 variants |
6 |
|
seasonality |
6 |
|
seizure |
6 |
|
severe acute respiratory syndrome - diagnosis - drug therapy - epidemiology - virology |
6 |
|
severe acute respiratory syndrome - diagnosis - immunology - virology |
6 |
|
severe acute respiratory syndrome - diagnosis - urine |
6 |
|
severe acute respiratory syndrome - drug therapy - virology |
6 |
|
sex characteristics |
6 |
|
survival rate |
6 |
|
t-cell functionality |
6 |
|
tenofovir hbsag surface antigen nucleoside analogue nucleotide analogue tdf |
6 |
|
tract |
6 |
|
transient elastography |
6 |
|
transmission |
6 |
|
vaccine seed strain selection |
6 |
|
vancomycin-resistant enterococci |
6 |
|
viral load - statistics & numerical data |
6 |
|
virus dna |
6 |
|
whole-genome sequencing |
6 |
|
acute kidney injury |
5 |
|
adenosine deaminase |
5 |
|
age distribution |
5 |
|
allogeneic stem cell transplantation |
5 |
|
amoxicillin - pharmacology - therapeutic use |
5 |
|
anti-bacterial agents - pharmacology - therapeutic use |
5 |
|
anti-inflammatory agents - administration & dosage |
5 |
|
antibody affinity |
5 |
|
antitubercular agents - therapeutic use |
5 |
|
antiviral |
5 |
|
apoptosis |
5 |
|
apoptosis - genetics |
5 |
|
arthralgia |
5 |
|
aspergillosis - etiology |
5 |
|
asthma |
5 |
|
b.1.1.7b.1.351 |
5 |
|
beta catenin - genetics - metabolism |
5 |
|
biliary tract diseases - chemically induced - diagnosis |
5 |
|
biological markers - blood |
5 |
|
bone marrow transplantation - immunology |
5 |
|
booster |
5 |
|
breath tests |
5 |
|
cadherins - antagonists and inhibitors - genetics |
5 |
|
caliciviridae infections - epidemiology - prevention and control - transmission |
5 |
|
case-control studies |
5 |
|
catheterization - adverse effects |
5 |
|
ccl22 |
5 |
|
cell line, tumor |
5 |
|
cell nucleus - metabolism |
5 |
|
ceruloplasmin - metabolism |
5 |
|
chi-square distribution |
5 |
|
china |
5 |
|
chinese |
5 |
|
cholangiopancreatography, endoscopic retrograde |
5 |
|
chronic obstructive pulmonary disease |
5 |
|
colonic neoplasms - etiology - metabolism |
5 |
|
colonic neoplasms - genetics - metabolism |
5 |
|
colonic neoplasms - pathology |
5 |
|
comorbidity |
5 |
|
copper/urine |
5 |
|
corticosteroid |
5 |
|
covid-19 severity |
5 |
|
cross infection - epidemiology - prevention and control - transmission |
5 |
|
cross infection - prevention and control - transmission - virology |
5 |
|
cytoplasm - metabolism |
5 |
|
disease outbreaks - prevention and control - statistics and numerical data |
5 |
|
disseminated infection recurrence rate |
5 |
|
dna methylation |
5 |
|
dna mutational analysis - methods |
5 |
|
drug dosage form comparison |
5 |
|
drug dose comparison |
5 |
|
e-cadherin |
5 |
|
endoscopic retrograde cholangiopancreatography |
5 |
|
endoscopic sphicterotomy |
5 |
|
eosinophilic phenotype |
5 |
|
epithelial cells - pathology |
5 |
|
epithelial-mesenchymal transition |
5 |
|
esomeprazole |
5 |
|
fecal-to-oral transmission |
5 |
|
fluorescent antibody technique |
5 |
|
gastroesophageal reflux disease |
5 |
|
gastrointestinal hemorrhage |
5 |
|
gene expression regulation, neoplastic |
5 |
|
gene silencing |
5 |
|
h1n1 virus |
5 |
|
h5n1 |
5 |
|
h9n2 |
5 |
|
hbcrag |
5 |
|
helicobacter infections - drug therapy - metabolism |
5 |
|
hematopoietic stem cell transplantation - adverse effects |
5 |
|
hepacivirus - genetics |
5 |
|
hepatitis b virus - genetics |
5 |
|
hepatitis c, chronic - drug therapy - virology |
5 |
|
hepatolenticular degeneration - complications - diagnosis - drug therapy - genetics - metabolism |
5 |
|
herpes zoster |
5 |
|
homeodomain proteins - analysis - physiology |
5 |
|
homeodomain proteins - physiology |
5 |
|
hospitalization |
5 |
|
hybrid immunity |
5 |
|
hypernatraemia |
5 |
|
igra |
5 |
|
immune checkpoint inhibitors |
5 |
|
immunocompromised host |
5 |
|
immunoprecipitation |
5 |
|
immunosuppressive agents - administration & dosage |
5 |
|
immunotherapy - methods |
5 |
|
infection control - methods |
5 |
|
infection control bundle |
5 |
|
influenza, human - mortality - therapy - virology |
5 |
|
influenza, human - prevention and control - transmission - virology |
5 |
|
inhalant abuse - complications |
5 |
|
interferon-alpha - therapeutic use |
5 |
|
intracellular signaling peptides and proteins - antagonists & inhibitors - genetics - metabolism |
5 |
|
intracellular signaling peptides and proteins - genetics - metabolism |
5 |
|
invasive mechanical ventilation |
5 |
|
invasive pneumococcal disease |
5 |
|
ketamine - administration and dosage - adverse effects |
5 |
|
lim-homeodomain proteins |
5 |
|
linearized hbsag |
5 |
|
liver diseases - diagnosis - etiology |
5 |
|
luciferases - metabolism |
5 |
|
lymphocyte count |
5 |
|
mesoderm - pathology |
5 |
|
methylprednisolone - administration & dosage |
5 |
|
mitochondria - metabolism |
5 |
|
muscle proteins - analysis - physiology |
5 |
|
muscle proteins - genetics - metabolism |
5 |
|
muscle proteins - physiology |
5 |
|
mycobacterium avium complex |
5 |
|
mycobacterium infections - etiology - microbiology |
5 |
|
mycobacterium tuberculosis - isolation & purification |
5 |
|
myeloperoxidase |
5 |
|
nasopharyngeal carcinoma |
5 |
|
nasopharyngeal specimen |
5 |
|
nasopharynx - virology |
5 |
|
neoplasm proteins - antagonists & inhibitors - genetics - metabolism |
5 |
|
neoplasm proteins - genetics - metabolism |
5 |
|
neutralizing antibody spike protein receptor binding domain |
5 |
|
non-hiv immunosuppression |
5 |
|
nontuberculous mycobacterium |
5 |
|
norovirus - genetics - isolation and purification |
5 |
|
nosocomial infection |
5 |
|
nucleosides - pharmacology - therapeutic use |
5 |
|
ofloxacin - pharmacology - therapeutic use |
5 |
|
omeprazole - pharmacology - therapeutic use |
5 |
|
outcomes |
5 |
|
p53 |
5 |
|
papillotomy |
5 |
|
plasma - immunology |
5 |
|
polyethylene glycols - therapeutic use |
5 |
|
polymerase chain reaction - methods |
5 |
|
population susceptibility |
5 |
|
pre-procedural mouthrinses |
5 |
|
primary prophylaxis |
5 |
|
prisma |
5 |
|
protein binding |
5 |
|
protein processing, post-translational - genetics |
5 |
|
pulse therapy, drug - methods |
5 |
|
pyrimidinones - pharmacology - therapeutic use |
5 |
|
recombinant proteins |
5 |
|
resistance |
5 |
|
respiratory tract infections |
5 |
|
respiratory tract infections - etiology - microbiology |
5 |
|
ribavirin |
5 |
|
rna, small interfering - genetics |
5 |
|
safety |
5 |
|
sars |
5 |
|
sars-cov-2 n501y variant |
5 |
|
satisfaction ratings |
5 |
|
secondary prophylaxis |
5 |
|
seroclearance |
5 |
|
seroprevalence |
5 |
|
severe acute respiratory syndrome - blood - complications - radiography |
5 |
|
severe acute respiratory syndrome - blood - mortality - virology |
5 |
|
severe acute respiratory syndrome - drug therapy |
5 |
|
sex distribution |
5 |
|
smell training |
5 |
|
snail1 |
5 |
|
sodium |
5 |
|
stomach neoplasms - genetics |
5 |
|
stomach neoplasms - genetics - metabolism |
5 |
|
stomach neoplasms - genetics - metabolism - pathology |
5 |
|
surgery |
5 |
|
trans-activators |
5 |
|
trans-activators - genetics - metabolism |
5 |
|
transcription factor ap-1 - genetics - metabolism |
5 |
|
transcription factors - genetics - metabolism |
5 |
|
transcription factors - metabolism - physiology |
5 |
|
transcription, genetic |
5 |
|
transcriptional activation |
5 |
|
tuberculosis reactivation |
5 |
|
tuberculosis, pulmonary - diagnosis - drug therapy - microbiology |
5 |
|
tumor cells, cultured |
5 |
|
tumor suppressor protein p53 - genetics - metabolism |
5 |
|
two-hybrid system techniques |
5 |
|
urologic diseases - chemically induced |
5 |
|
viral persistence |
5 |
|
viral suppression |
5 |
|
voc |
5 |
|
week 12 |
5 |
|
week 24 |
5 |
|
13c-urea breath test |
4 |
|
5-asa |
4 |
|
abdominal pain - microbiology |
4 |
|
adenoma |
4 |
|
adenomatous polyposis coli - complications - drug therapy |
4 |
|
adenomatous polyps |
4 |
|
adenovirus |
4 |
|
advanced kidney disease |
4 |
|
algorithms |
4 |
|
amoxicillin - therapeutic use |
4 |
|
antibiotics |
4 |
|
anticarcinogenic agents - administration & dosage |
4 |
|
anticarcinogenic agents - pharmacology - therapeutic use |
4 |
|
asia |
4 |
|
asia - epidemiology |
4 |
|
autoantibody |
4 |
|
b cell |
4 |
|
ba.2.86 |
4 |
|
bacterial infections - diagnosis - drug therapy - epidemiology |
4 |
|
bariatric surgery - mortality |
4 |
|
body mass index |
4 |
|
calcium |
4 |
|
carbapenemase-producing enterobacteriaceae |
4 |
|
cardiac complications |
4 |
|
cecal diseases - diagnosis - parasitology |
4 |
|
chemoprevention |
4 |
|
chemoprophylaxis |
4 |
|
chronic infection |
4 |
|
ckd |
4 |
|
clarithromycin - therapeutic use |
4 |
|
clinical trial |
4 |
|
clinical trials as topic |
4 |
|
colorectal |
4 |
|
colorectal cancer |
4 |
|
colorectal carcinoma |
4 |
|
colorectal neoplasms - diagnosis - epidemiology - etiology - prevention & control |
4 |
|
colorectal neoplasms - epidemiology |
4 |
|
colorectal neoplasms - etiology - prevention and control |
4 |
|
community-acquired infections - epidemiology - microbiology - physiopathology |
4 |
|
covid-19 vaccines |
4 |
|
cox-2 inhibitors |
4 |
|
crohn's disease |
4 |
|
depression |
4 |
|
diabetes mellitus, type 2 - prevention & control |
4 |
|
diet - adverse effects |
4 |
|
double-blind method |
4 |
|
drug therapy, combination - methods |
4 |
|
eg.5 |
4 |
|
empirical first-line eradication |
4 |
|
endemicity |
4 |
|
enterococcus peritonitis |
4 |
|
epidemiology - trends |
4 |
|
evolution |
4 |
|
fatty liver - surgery |
4 |
|
gastric balloon |
4 |
|
gastric bypass - statistics & numerical data |
4 |
|
gastroesophageal reflux - drug therapy - psychology |
4 |
|
gastroesophageal reflux - psychology |
4 |
|
gastrointestinal colonization |
4 |
|
gastroplasty - statistics & numerical data |
4 |
|
gerd |
4 |
|
gram-positive bacterial infections - drug therapy - etiology |
4 |
|
graves' disease |
4 |
|
health economics |
4 |
|
helicobacter infections - drug therapy |
4 |
|
helicobacter pylori - drug effects |
4 |
|
helicobacter pylori - treatment |
4 |
|
iga |
4 |
|
immune impairment |
4 |
|
immunocompetence |
4 |
|
immunodeficiency |
4 |
|
inactivated influenza |
4 |
|
inflammatory bowel disease |
4 |
|
interferon-gamma |
4 |
|
intussusception - diagnosis - parasitology |
4 |
|
jn.1 |
4 |
|
l336m |
4 |
|
laryngeal diseases - psychology |
4 |
|
laryngopharyngeal reflux |
4 |
|
laryngoscopy |
4 |
|
levofloxacin |
4 |
|
liver transplant |
4 |
|
logistic models |
4 |
|
mass screening - methods |
4 |
|
middle east respiratory syndrome coronavirus (mers-cov) |
4 |
|
mouse |
4 |
|
mucosal immunity |
4 |
|
mycobacteriosis |
4 |
|
mycosis |
4 |
|
non-alcoholic fatty liver disease |
4 |
|
novel coronaviruses |
4 |
|
nsaids |
4 |
|
obesity - surgery |
4 |
|
ofloxacin - therapeutic use |
4 |
|
omicron variant |
4 |
|
pa |
4 |
|
paracetamol |
4 |
|
parainfluenza virus |
4 |
|
peritoneal dialysis - adverse effects |
4 |
|
peritonitis - drug therapy - microbiology |
4 |
|
pge2 |
4 |
|
pharyngeal diseases - psychology |
4 |
|
phylogenetic tree |
4 |
|
predictive value of tests |
4 |
|
proton pump inhibitor |
4 |
|
proton pump inhibitors - therapeutic use |
4 |
|
psychiatric status rating scales |
4 |
|
quality of life |
4 |
|
reactive dermatosis |
4 |
|
registries |
4 |
|
renal replacement therapy |
4 |
|
risk reduction behavior |
4 |
|
secular trend |
4 |
|
severe acute respiratory syndrome - drug therapy - physiopathology - virology |
4 |
|
severe acute respiratory syndrome coronavirus (sars-cov) |
4 |
|
sex factors |
4 |
|
sweet's syndrome |
4 |
|
thiopurine |
4 |
|
third dose |
4 |
|
trend |
4 |
|
trichuriasis - complications |
4 |
|
trichuris - isolation and purification |
4 |
|
ulcerative colitis |
4 |
|
varicella zoster virus |
4 |
|
vitamin d |
4 |
|
weight loss - physiology |
4 |
|
airborne |
3 |
|
antibody-dependent cell cytotoxicity |
3 |
|
antimicrobial |
3 |
|
arginine |
3 |
|
artificial ventilation |
3 |
|
biofilm |
3 |
|
cardiac magnetic resonance imaging |
3 |
|
cerebrovascular accident |
3 |
|
chronic disease |
3 |
|
clinical practice |
3 |
|
colorectal neoplasms - etiology |
3 |
|
constipation - complications |
3 |
|
contact tracing |
3 |
|
cross-reactive |
3 |
|
dentistry |
3 |
|
droplet |
3 |
|
elemedicine |
3 |
|
epitope mapping |
3 |
|
epitopes, b-lymphocyte - immunology |
3 |
|
erythema nodosum |
3 |
|
esophagoscopy |
3 |
|
facility design and construction |
3 |
|
fluoride |
3 |
|
guideline adherence |
3 |
|
gut microbiota |
3 |
|
h1n1 subtype |
3 |
|
hand hygiene |
3 |
|
helicobacter infections - diagnosis - therapy |
3 |
|
hemagglutinin glycoproteins, influenza virus - immunology |
3 |
|
housing |
3 |
|
iccov |
3 |
|
infection |
3 |
|
infection control |
3 |
|
infection controlt |
3 |
|
influenza a virus |
3 |
|
iterferon gamma |
3 |
|
kidney transplantation |
3 |
|
lopinavir‐ritonavir |
3 |
|
management |
3 |
|
mycobacterium |
3 |
|
pd-1-enhanced dna vaccine |
3 |
|
penicillium marneffei |
3 |
|
physician's practice patterns |
3 |
|
practice guidelines as topic |
3 |
|
preprocedural mouthwash |
3 |
|
proactive infection control |
3 |
|
professional practice |
3 |
|
recovered |
3 |
|
respiratory pathogens |
3 |
|
severe acute respiratory syndrome - epidemiology - transmission - virology |
3 |
|
statistics, nonparametric |
3 |
|
survey |
3 |
|
synbiotic |
3 |
|
troponin |
3 |
|
urban population |
3 |
|
vaccine immunogenicity |
3 |
|
virology |
3 |
|
virulence factors |
3 |
|
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use |
2 |
|
3c-like protease |
2 |
|
analysis of variance |
2 |
|
anti-ulcer agents - therapeutic use |
2 |
|
antibodies, viral - immunology |
2 |
|
antifungal agents - therapeutic use |
2 |
|
antiviral efficacy |
2 |
|
antiviral resistance |
2 |
|
asian continental ancestry group |
2 |
|
azathioprine |
2 |
|
barthel index |
2 |
|
blood donors - statistics & numerical data |
2 |
|
cohort |
2 |
|
combined multichannel intraluminal impedance-ph monitoring |
2 |
|
complication |
2 |
|
coronavirus disease 2019 |
2 |
|
cross infection - ethnology - mortality |
2 |
|
day care - statistics and numerical data |
2 |
|
duodenal ulcer - epidemiology - microbiology - pathology |
2 |
|
efficacy |
2 |
|
elderly-onset |
2 |
|
electric impedance |
2 |
|
endoscopy, gastrointestinal |
2 |
|
erosive esophagitis |
2 |
|
esophageal neoplasms - epidemiology - microbiology - pathology |
2 |
|
esophageal ph monitoring |
2 |
|
esophageal ph monitoring - instrumentation |
2 |
|
esophagitis - drug therapy - epidemiology - physiopathology |
2 |
|
face masks |
2 |
|
foot and mouth disease |
2 |
|
functional heartburn |
2 |
|
functional status |
2 |
|
gastroesophageal reflux - diagnosis |
2 |
|
gastroesophageal reflux - drug therapy - epidemiology - physiopathology |
2 |
|
hand |
2 |
|
helicobacter infections - epidemiology - microbiology - pathology |
2 |
|
helicobacter pylori - pathogenicity |
2 |
|
hepatitis a |
2 |
|
hepatitis d |
2 |
|
hepatitis e |
2 |
|
homes for the aged - statistics and numerical data |
2 |
|
hospitalization - statistics and numerical data |
2 |
|
hyperammonaemia |
2 |
|
ibd |
2 |
|
immunocompromised host - immunology |
2 |
|
immunoglobulins - immunology - isolation & purification - therapeutic use |
2 |
|
immunosuppressive agents - adverse effects |
2 |
|
influenza a (h1n1) 2009 |
2 |
|
influenza vaccination |
2 |
|
influenza vaccines - administration and dosage - immunology |
2 |
|
influenza, human - immunology - prevention & control |
2 |
|
influenza, human - mortality - prevention and control |
2 |
|
injections, intradermal |
2 |
|
institutionalization |
2 |
|
institutionalized elderly |
2 |
|
intestinal metaplasia |
2 |
|
low dose |
2 |
|
lymphocytes - immunology |
2 |
|
mediastinal emphysema - etiology - radiography |
2 |
|
metaplasia |
2 |
|
multichannel intraluminal impedance, esophageal |
2 |
|
neuroendocrine tumours |
2 |
|
non-erosive reflux disease |
2 |
|
nursing home |
2 |
|
nursing home older adults |
2 |
|
nursing homes - statistics and numerical data |
2 |
|
opportunistic infections - diagnosis/epidemiology |
2 |
|
pandemic influenza a h1n1 |
2 |
|
ph monitoring |
2 |
|
pneumococcus |
2 |
|
pneumocystis jiroveci - isolation & purification |
2 |
|
pneumocystis jirovecii - *isolation & purification |
2 |
|
pneumomediastinum |
2 |
|
pneumonia - ethnology - mortality |
2 |
|
pneumonia, pneumocystis - diagnosis - drug therapy |
2 |
|
pneumonia, pneumocystis - diagnosis/epidemiology |
2 |
|
pneumothorax |
2 |
|
precancerous conditions - epidemiology - microbiology - pathology |
2 |
|
reference values |
2 |
|
renal medicine |
2 |
|
severe acute respiratory syndrome - complications - drug therapy - radiography |
2 |
|
simnotrelvir |
2 |
|
steroid-dependent ulcerative colitis |
2 |
|
stomach neoplasms - epidemiology - microbiology - pathology |
2 |
|
stomach ulcer - epidemiology - microbiology - pathology |
2 |
|
sunitinibs |
2 |
|
systematic review |
2 |
|
time trend |
2 |
|
tomography, x-ray computed |
2 |
|
trial proposal |
2 |
|
access to information |
1 |
|
adrenal cortex hormones - therapeutic use |
1 |
|
antitubercular agents |
1 |
|
antitubercular agents - adverse effects |
1 |
|
antivirals |
1 |
|
bacterial infections - diagnosis - pathology - radiography |
1 |
|
clinical research |
1 |
|
computed tomography |
1 |
|
computer simulator |
1 |
|
diagnostic tests, routine - methods |
1 |
|
dose-sparing |
1 |
|
drug research |
1 |
|
drug safety |
1 |
|
empirical antimicrobials |
1 |
|
endoscopic retrograde cholangiopancreatography (ercp) |
1 |
|
ercp mechanical simulator |
1 |
|
health knowledge, attitudes, practice |
1 |
|
health personnel |
1 |
|
homes for the aged |
1 |
|
institutionalized older adults |
1 |
|
lower respiratory tract infections |
1 |
|
lupus nephritis - therapy |
1 |
|
mantoux |
1 |
|
mastoiditis |
1 |
|
mastoiditis - diagnosis - pathology - radiography |
1 |
|
maternal immunization |
1 |
|
meta-analysis |
1 |
|
microneedles |
1 |
|
monoclonal antibodies |
1 |
|
nirsevimab |
1 |
|
nursing homes |
1 |
|
pathogens |
1 |
|
peritoneal dialysis |
1 |
|
peritoneal dialysis, continuous ambulatory |
1 |
|
pneumococcal disease |
1 |
|
pneumococcal vaccines - administration and dosage - adverse effects |
1 |
|
radiology - methods |
1 |
|
review |
1 |
|
rsv |
1 |
|
rsv vaccine |
1 |
|
severe acute respiratory syndrome coronavirus 2 |
1 |
|
simulation training |
1 |
|
steroids |
1 |
|
treatment |
1 |
|
tuberculosis |
1 |
|
tuberculosis, lymph node - drug therapy |
1 |
|
vaccine delivery |
1 |
|
vaccine device |
1 |
